Dr. David Haefliger | Pharmacology | Best Researcher Award

Dr. David Haefliger, CHUV, Switzerland

Dr. David Haefliger is a distinguished expert in pharmacology, recognized for his groundbreaking research and contributions to the field. With a strong background in drug interactions and therapeutic efficacy, Dr. Haefliger’s work has significantly advanced the understanding of pharmacological mechanisms and their clinical applications. His research is widely published in leading journals and has been instrumental in shaping contemporary practices in pharmacology. As a recipient of the Best Researcher Award, Dr. Haefliger continues to drive innovation and excellence in his field, demonstrating an unwavering commitment to advancing medical science and improving patient outcomes.

Profile

Scoopus

Education

Dr. David Haefliger has an extensive educational and professional background in the medical field. He earned his Bachelor’s degree in Medicine in June 2012 and his Master’s degree in Medicine in June 2015, both from the University of Lausanne, Switzerland. In addition to his foundational degrees, he completed the Swiss Board Examination in General Internal Medicine in June 2019, and he is an Advanced Cardiovascular Life Support Provider, certified in October 2016. Most recently, in 2024, Dr. Haefliger obtained a Certificate of Advanced Studies in Clinical Research from the University of Lausanne, further solidifying his expertise and commitment to advancing clinical research.

Proffesional Experience

Since February 2022, Dr. David Haefliger has been working in the Service of Clinical Pharmacology at the Department of Medicine, University Hospital Lausanne, Switzerland. Prior to this role, he served in the Service of Infectious Diseases at the University Hospital Lausanne from November 2019 to October 2021. Dr. Haefliger also gained valuable experience in the Intensive Care Unit at Fribourg Hospital from November 2018 to October 2019. His career began in Internal Medicine at Fribourg Hospital, where he worked from November 2015 to October 2018.

Publication Top Notes

Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C. Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Semin Dial. 2024.
Dao K, Buettcher M, Golhen K, et al. Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. J Clin Pharmacol. 2024.
Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP-1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services. BMJ Open. 2024.
Grütter S, Haefliger D, Wuerzner G, Yerly P, Bouchardy J, Rutz T. The Deleterious Consequences of a Nonsteroidal Anti-inflammatory Drug in an Eisenmenger Patient. CJC Pediatr Congenit Heart Dis. 2023.
Haefliger D, Marzolini C, Lamoth F, Pabst T, Buclin T, Livio F. Clinically Relevant Bidirectional Drug-Drug Interaction Between Midostaurin and Voriconazole. Br J Clin Pharmacol. 2023.
Haefliger D, Livio F. Pharmacothérapie – Nouveaux Médicaments et Vaccins Disponibles en 2022 [Pharmacotherapy: New Drugs and Vaccines in 2022]. Rev Med Suisse. 2023.
Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 Syndrome in Outpatients: A Cohort Study. J Gen Intern Med. 2022.
Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, Risk Factors, and Clinical Course of SARS-CoV-2 Infected Patients in a Swiss University Hospital: An Observational Retrospective Study. PLoS One. 2020.
Grandjean T, Haefliger D, Arroyo D, Cook S. Coronary Sinus Reduction for the Treatment of Refractory Angina. Cardiovasc Med. 2018.
Haefliger D, Chuard C. Légionellose [Legionellosis]. Rev Med Suisse. 2017.

Articles with Acknowledgments (as a member of the RegCOVID Study Group):

Galperine T, Choi Y, Pagani JL, et al. Temporal Changes in Fecal Microbiota of Patients Infected with COVID-19: A Longitudinal Cohort. BMC Infect Dis. 2023.
COVID-19 Host Genetics Initiative. Mapping the Human Genetic Architecture of COVID-19. Nature. 2021.
Bibert S, Guex N, Lourenco J, et al. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol. 2021.